The Latest Breaking News from Krystal Biotech

Krystal Biotech shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

The U.S. Food and Drug Administration approved a gene therapy for dystrophic epidermolysis bullosa, also known as butterfly disease.

Upgrades

The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ:KRYS) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with dystrophic epidermolysis bullosa (DEB). The regulatory agency has granted  Priority Review designation and assigned a target actin date of February 17,…

The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ:ELDN) Investigational New Drug (IND) application to evaluate Tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant. Eledon shares traded in a range of $2.89 to $3.16 on a day volume of 31.27 thousand…

Krystal Biotech, Inc. (NASDAQ: KRYS) submits biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of B-VEC (beremagene geperpavec) in the treatment of patients with dystrophic epidermolysis bullosa (DEB).

A Relative Strength Rating upgrade for KrystalBiotech shows improving technical performance.

KrystalBiotech sees its Relative Strength Rating enter the elite 90-plus level.

Krystal Biotech Inc (NASDAQ: KRYS) shares have potential to nearly double from current levels, according to an analyst at BofA Securities.